Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.72 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 15/20 | 1.00 |
| ▸ | DRD5 | P21918 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30685980 | 1.00 | DRD1 (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| SCHEMBL20415945 | 0.99 | DRD1 (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| SCHEMBL11398674 | 0.99 | DRD1 (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| Hydrochloric Acid SCHEMBL7205098 | 0.97 | DRD1 (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| Bromide SCHEMBL11707024 | 0.90 | KDM4E (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| SCHEMBL11712694 | 0.88 | DRD1 (1.00) | DRD1DRD5MAPK1LMNAHTR2A | |
| SCHEMBL9764438 | 0.85 | DRD1 (0.82) | DRD1DRD5MAPK1LMNAHTR2A | |
| Sch-23390 SCHEMBL2916216 | 0.84 | DRD1 (1.00) | DRD1DRD5MAPK1LMNADRD2 | |
| SCHEMBL469504 | 0.84 | DRD1 (0.81) | DRD1DRD5MAPK1LMNAHTR2A | |
| SCHEMBL31676580 | 0.84 | DRD1 (0.81) | DRD1DRD5MAPK1LMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806276-A1 | Method for post mortem diagnosis of Alzheimer's Disease (AD) | Red Bull GmbH (AT) | 2014-11-26 | — | — | EP | claimed |
| US-12268901-B2 | Targeting cell tropism receptors to inhibit cytomegalovirus infection | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-08 | — | — | US | disclosed |
| US-20230034732-A1 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | UNIVERSITY OF MASSACHUSETTS | 2023-02-02 | — | — | US | disclosed |
| US-11484570-B2 | Targeting cell tropism receptors to inhibit cytomegalovirus infection | UNIVERSITY OF MASSACHUSETTS (US) | 2022-11-01 | — | — | US | disclosed |
| US-20200376077-A1 | Targeting Cell Tropism Receptors to Inhibit Cytomegalovirus Infection | UNIVERSITY OF MASSACHUSETTS | 2020-12-03 | — | — | US | disclosed |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3609521-A1 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | University of Massachusetts (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191603-A1 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | UNIVERSITY OF MASSACHUSETTS (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-2806276-A1 | Method for post mortem diagnosis of Alzheimer's Disease (AD) | Red Bull GmbH (AT) | 2014-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | ADRA2A 63/4885ADRA2B 176/4885ADRA2C 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.